Revenue jumps 23pc at Nurofen owner
Nurofen owner Reckitt Benckiser has reported a 23pc jump in net revenue over the first half of the year to £6.1bn (€6.9bn).
Pre-tax profits rose 9.5pc to £1.1bn.
It has now raised its revenue growth targets to 14pc-15pc at constant exchange rates, with like-for-like revenue growth expected to reach the upper end of 2pc-3pc.
Chief executive Rakesh Kapoor said: "Delivering growth and the successful integration of MJN (Mead Johnson Nutrition) remain our key priorities. Quarter two was a quarter of progress against both of these priorities.
"MJN integration is well on track, with IFCN (Infant Formula and Child Nutrition) performance exceeding expectations and synergies being delivered."
He said that the restructuring plan, which reorganised the business into two business units - Health and Hygiene Home - was driving "greater focus and energy" at the company.
"I am confident that as we fully realise the benefits of RB 2.0, we will deliver outperformance in both business units."
Reckitt Benckiser shares were at the top of the FTSE 10 after rising more than 8pc.